Fujifilm Sonosite has received US Food and Drug Administration’s (FDA) 510(k) and CE mark approval in Europe for its new portable ultrasound system, SonoSite Edge II.
Featuring advanced DirectClear technology, the new portable ultrasound system has been developed to be used in emergency medicine and critical care applications.
DirectClear technology is said to enhance transducer performance by increasing penetration and contrast resolution.
The transducer technology, along with new wide-angle display, provides clinicians with better viewing angles.
The system also uses armored cable technology to maintain image quality over the life of transducers.
Fujifilm Sonosite senior vice president and chief medical officer Dr Diku Mandavia said: . "The Edge II ultrasound system stays true to the SonoSite legacy of durability, reliability, and ease of use.
"However, we also incorporated enhancements to accelerate the time to image acquisition, enabling clinicians to make more confident decisions and focus on what matters most, the patient."
Last November, Fujifilm Sonosite received FDA 510(k) approval for its new medical visualization solution, iViz, a platform that integrates ultrasound with medical IT.
The firm also received CE mark approval for the solution in September, which was designed for clinical users, ranging from hospital settings to clinics in remote villages, to carry out ultrasound when and where it is needed.
Image: Fujifilm has launched new portable ultrasound system SonoSite Edge II. Photo: courtesy of FUJIFILM SonoSite, Inc.